Aarhus University Hospital researchers reported in The British Journal of Psychiatry on October 23, 2026 an interrupted time-series analysis of Danish national registers from 1996 to 2023, identifying 3,042 people with schizophrenia who started a GLP-1 receptor agonist. When the drug was started for diabetes, HbA1c, LDL cholesterol, and triglycerides fell by 11.4%, 6.2%, and 14.8%; when started for overweight, they fell by 3.4%, 4.9%, and 12.7%, all statistically significant. The authors used LDL and triglycerides as stand-ins for weight loss and say the results suggest benefits seen in randomized trials in schizophrenia extend to routine care; the design has no comparison group.
BioXcel Therapeutics (NASDAQ: BTAI) filed for Chapter 11 bankruptcy protection Thursday August 27, 2026 after telling investors it lacked cash to fund operations through the end of August despite securing a bridge loan earlier the same week. Teva Pharmaceutical Industries (NYSE: TEVA) signed a stalking-horse asset sale agreement Friday August 28, 2026 to acquire BioXcel's lead neuroscience asset for $57.5 million upfront plus up to $67.5 million in milestone payments through a court-supervised auction. The lead asset is a novel dexmedetomidine sublingual film under FDA review for at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, with a PDUFA target action date of November 14, 2026. The stalking-horse bid sets the floor price for competing bidders. Teva positioned the acquisition as consistent with its 'Pivot to Growth' strategy and disciplined business development approach.